Infliximab is a lab-made antibody that works by locking onto a protein called TNF-alpha, one of the main drivers of harmful inflammation in conditions like Crohn’s disease, rheumatoid arthritis, ulcerative colitis, and psoriasis. By neutralizing TNF-alpha before it can trigger an immune response, infliximab dials down the overactive inflammation that damages tissues and causes symptoms. But binding TNF-alpha is only part of the story. The drug also kills certain immune cells that are fueling the disease, which is why it can produce such dramatic results for some patients.
How It Targets TNF-Alpha
TNF-alpha exists in two forms in your body. One is a free-floating (soluble) version that circulates in the blood and tissues. The other is anchored directly to the surface of immune cells. Infliximab binds to both forms with high affinity, and once it latches on, the resulting complex is stable, meaning the TNF-alpha molecule is effectively locked up and can no longer attach to its receptors on other cells. Without that receptor connection, the chain reaction of inflammation never fires.
This matters because TNF-alpha is a signaling molecule. Normally it tells other immune cells to ramp up their activity, recruit more inflammatory cells to a site, and release additional inflammatory chemicals. In autoimmune diseases, this process runs out of control. Infliximab intercepts the signal at its source.
Killing the Cells Behind Inflammation
Neutralizing TNF-alpha alone doesn’t fully explain infliximab’s effectiveness. The drug also triggers the death of activated immune cells, specifically certain T cells and monocytes, that carry TNF-alpha on their surface. When infliximab binds to the membrane-bound TNF-alpha on these cells, it activates an internal self-destruct sequence called apoptosis. This happens through a specific pathway involving enzymes called caspases, which essentially disassemble the cell from the inside.
Research published in Gastroenterology showed that this binding shifts the balance of pro-death and pro-survival signals within the cell, tipping it toward programmed death. Importantly, this is a targeted process. Infliximab preferentially kills activated immune cells, the ones actively producing TNF-alpha and driving disease, rather than wiping out the entire immune system. Earlier theories suggested that infliximab might also destroy these cells through complement-mediated lysis (a different immune mechanism that punches holes in cell membranes), but more recent evidence indicates the caspase-driven apoptosis pathway is the primary mechanism at therapeutic concentrations.
How It’s Given and How Quickly It Works
Infliximab is delivered as an intravenous infusion, meaning it’s administered through a vein, typically at a clinic or infusion center. The standard schedule starts with three “loading” infusions at weeks 0, 2, and 6. After that, maintenance infusions follow every 8 weeks. Each infusion session usually takes about two hours, sometimes longer if the infusion rate needs to be slowed for tolerability.
The dose is weight-based. For Crohn’s disease and ulcerative colitis, the standard is 5 mg per kilogram of body weight. For rheumatoid arthritis, it’s lower at 3 mg/kg, and it’s typically combined with methotrexate. Some patients notice improvement within the first couple of weeks, but the full effect builds over the induction period. Patients who haven’t responded by week 14 are unlikely to benefit from continued treatment.
How Long It Stays in Your System
Infliximab has a median effective half-life of about 5.6 days, though this varies significantly from person to person. Several factors speed up how quickly your body clears the drug. Low albumin levels (a blood protein), higher body weight, and the development of antibodies against infliximab all increase clearance. Antibodies against the drug are particularly impactful, increasing clearance by roughly 259%.
Because of this variability, many doctors now use therapeutic drug monitoring, checking blood levels of infliximab between infusions to make sure enough drug remains in your system. The target “trough” concentration, meaning the lowest level between infusions, is generally 3 to 7 micrograms per milliliter. Falling below this range is associated with worse outcomes, while staying within it allows for more efficient dosing without unnecessary exposure.
Why Some People Lose Response Over Time
About 24% of patients develop antibodies against infliximab. Because infliximab is partly derived from mouse protein (it’s a chimeric antibody, meaning part mouse and part human), the immune system can recognize it as foreign and mount a response against it. These anti-drug antibodies bind to infliximab in the bloodstream, neutralizing it before it can reach its target and accelerating its removal from the body.
The clinical impact is significant. In a large trial of 615 patients, only 35% of those with anti-drug antibodies achieved remission at 30 weeks, compared to 54% of those without antibodies. Patients who developed these antibodies were also more likely to experience disease worsening over a year and more likely to discontinue treatment. Taking an additional immunosuppressant alongside infliximab reduces the risk of antibody formation, which is one reason why combination therapy is standard in many treatment protocols.
Infection Risk and Safety Considerations
Because infliximab suppresses part of the immune system, it carries a real risk of serious infections. The FDA’s boxed warning highlights tuberculosis as a specific concern, including reactivation of latent TB that may have been dormant for years. Before starting infliximab, you’ll be tested for latent TB, and if the test is positive, treatment for the latent infection needs to begin first.
Other infections of concern include invasive fungal infections such as histoplasmosis, as well as bacterial infections from organisms like Legionella and Listeria. The risk is higher in patients taking additional immunosuppressants like corticosteroids or methotrexate alongside infliximab. The boxed warning also notes a small increased risk of certain cancers, particularly lymphoma, though the absolute risk remains low.
Biosimilars and the Original
Several biosimilar versions of infliximab are now FDA-approved and widely used. These are manufactured to have no clinically meaningful differences from the original product (Remicade) in terms of safety, purity, and potency. Large studies, both before and after these products reached the market, confirm similar clinical effectiveness without increased rates of antibody formation. Patients who switch from the original to a biosimilar, or between biosimilars, show no negative impact on how well the drug works or how safe it is. The choice between the original and a biosimilar is largely a matter of cost and insurance coverage.